longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

CCHT

000661

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -82.56, below the reasonable range, cheaper than 91.74% of the time in the past 5 years, and the industry ranks 212/221, the industry Median 22.98.

-82.56xP/E
¥71.36Stock price
¥-0.86Earnings per share
-82.56xP/E
Stock price¥71.36Earnings per share¥-0.86

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
16.28x
Typical range
10.46x–22.82x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 22.98x
019385776

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 22.98x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
688506SHBIOKIN PHARMACEUTICAL
-63.68x15.13%¥100.16B
000661SZCCHT
-82.56x588.46%¥29.11B
300255SZCSBIO
-60.56x--¥20.93B
300436SZCosunter
-65.39x--¥14.34B
300363SZPorton
-77.38x105.56%¥11.99B
000908SZCSPC Jingfeng
-253.65x--¥10.77B
301263SZT&K
-2,117.18x--¥10.02B
002099SZHISOAR
-50.99x--¥8.63B
688505SHFudan-Zhangjiang
-61.74x--¥7.80B
688176SHAsieris
-14.54x8.11%¥7.16B
600252SHZhongheng Group
-16.08x--¥6.94B
000813SZDEZHAN HEALTHCARE
-18.61x--¥6.71B
002737SZSFPM
-25.30x--¥6.57B
300267SZER-KANG
-17.47x--¥6.52B
002424SZGZBL
-48.98x--¥6.18B
600422SHKPC
-28.87x53.62%¥6.13B
000566SZHAINAN HAIYAO
-12.20x--¥5.90B
002082SZWBDE
-48.34x--¥5.68B
688658SHYKYY
-20.99x--¥5.63B
300006SZLummy
-42.57x--¥5.40B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.